Fig. 2. Tumour-derived CCL20 production co-localises to areas of ERK activation and correlates with progressive states of cancer.

a Representative results of serial sections of breast cancer (n = 6), melanoma (n = 6) and HNSCC (n = 6) stained with anti-CCL20 or anti-pERK1/2 antibodies are shown [scale bars represent 200 µm]. b Representative high and low expression of CCL20 and pERK in tumour tissue microarrays. Classifications of CCL20^high, CCL20^low, pERK^high and pERK^low were used for further statistical evaluation of tumour tissue microarrays. c Kaplan–Meier graph showing cumulative survival of breast cancer patients as a percentage to follow-up time in months. The follow-up time in this series was calculated from the date of primary tumour excision. Clinical records and follow-up times were obtained from all patients with a median observation time of 77 months (range 9–84 months). Statistical analyses were performed using the Chi-Square test and SPSS software.